Mercado Global de Hepatite E – Tendências do Setor e Previsão para 2029

Análise e dimensão do mercado da hepatite E

Espera-se que o mercado da hepatite E testemunhe um crescimento significativo durante o período de previsão. Os mercados emergentes e o enorme investimento em investigação e desenvolvimento são os factores responsáveis ​​pelo crescimento deste mercado. O crescimento do mercado da hepatite E potenciado pelos casos crescentes de hepatite E e pelo aumento das atividades de investigação e desenvolvimento conduzidas por muitas empresas farmacêuticas. Além disso, os avanços nas opções de tratamento e a presença de unidades de saúde bem estabelecidas são alguns dos fatores impactantes para a procura do mercado da Hepatite E. O COVID-19 também teve um grande impacto no crescimento do mercado.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado global de hepatite E no período de previsão 2022-2029. O mercado da hepatite E tende a ter um CAGR saudável no período de previsão mencionado. Além dos insights de mercado, tais como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge também inclui análises especializadas aprofundadas , epidemiologia do doente, pipeline analysis, análise de preços e enquadramento regulamentar.

Âmbito e segmentação do mercado da hepatite E

Market Definition

Hepatitis E, also known as hepatitis E virus (HEV), is a viral liver inflammation disease. This virus is spread primarily by faecal-oral transmission and contaminated food and water. Although hepatitis E virus often causes acute and self-limiting infection as virus usually does not take too long-term illness and resolves itself. However, immunocompromised patients can lead to life-threatening conditions or even death.   

Global Hepatitis E Market Dynamics

Drivers

• Prevalence of Hepatitis E

According to World Health Organizations in July 2020, each year there is an estimated 20 million Hepatitis E infections worldwide which leads to a 3.3 million symptomatic cases of hepatitis E. Thus, it boosts the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increasing Demand for Retail Pharmacies

Rise in the number of hepatitis E therapeutics being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

• Increase in Geriatric Population

The geriatric population is expected to increase the patient population globally, which boots the global hepatitis E market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. This boost the market growth.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global hepatitis E market over a forecast period.

• High Cost

The huge expenditure associated with Hepatitis E treatment medications surely hamper the market growth.

This global hepatitis E market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hepatitis E market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Hepatitis E Market            

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials. The unavailability of the specific COVID-19 tests presented positive opportunities for the manufacturers to introduce their COVID-19 diagnostic kits. Many major market players as well as many start-ups from several countries are gathering up to boost the market growth.

Global Hepatitis E Market Scope

The global hepatitis E market is segmented on the basis of drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Antiviral Drugs
• Interferons
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Hepatitis E Market Regional Analysis/Insights

The global hepatitis E market is analysed and market size insights and trends are provided by drug class, distribution channel and end-user as referenced above.

The major countries covered in the global hepatitis E market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global hepatitis E market throughout the forecasted period due to the high prevalence of hepatitis E, high diagnostic rate and presence of sophisticated medical facilities in order to optimize the treatment for patient suffering from the hepatitis E.

Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Cenário competitivo e análise global da quota de mercado da hepatite E

O panorama competitivo do mercado global da hepatite E fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado global da hepatite E.

Os principais players que trabalham no mercado global de Hepatite E incluem:

• (EUA)
• GSK plc (Reino Unido)
• Novartis AG (Suíça)
• Mylan NV (EUA)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (França)
• Boehringer Ingelheim International GmbH. (Alemanha)
• AstraZeneca (Reino Unido)
• Johnson & Johnson Private Limited (EUA)
• Bayer AG (Alemanha)
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd. (Suíça)
• Empresa Bristol-Myers Squibb (EUA)
• Cadila Pharmaceuticals (Índia)

SKU-53752